臨床検査55巻1号

2011年01月発行

今月の主題 -ミクログロブリン－その多様な病因，病態と検査アプローチ 各論 〈病態疾患と動態解析〉

多発性骨髄腫とβ₂-ミクログロブリン―国際ステージ分類

著者： 大口裕人¹ 張替秀郎²

所属機関： ¹東北大学病院血液免疫科 ²東北大学病院・大学院医学系研究科血液免疫病学分野

ページ範囲：P.51 - P.57

多発性骨髄腫は，B細胞の最終分化段階にある形質細胞が腫瘍化した疾患である．骨髄腫患者の予後は多様で，6か月以内から10年以上の経過まで幅広く，予後因子に基づく層別化は適切な治療を行ううえで重要である．2005年，International Myeloma Working Groupより，血清β₂-ミクログロブリン値および血清アルブミン値を用いた国際ステージ分類(ISS)が提唱された．ISSは従来のDurie/Salmon分類と比較し簡便かつ予後との相関性も優れており，現在，臨床の現場で広く用いられている．

参考文献

1) Hideshima T, Mitsiades C, Tonon G, et al:Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer　7：585-598，2007

2) Carbone PP, Kellerhouse LE, Gehan EA:Plasmacytic myeloma. A study of the relationship of survival to various clinical manifestations and anomalous protein type in 112 patients. Am J Med　42：937-948，1967

3) Durie BG, Salmon SE:A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer　36：842-854，1975

4) Cassuto JP, Krebs BP, Viot G, et al:beta 2 Microglobulin, a tumour marker of lymphoproliferative disorders. Lancet　2：108-109，1978

5) Bataille R, Durie BG, Grenier J:Serum beta2 microglobulin and survival duration in multiple myeloma:a simple reliable marker for staging. Br J Haematol　55：439-447，1983

6) Durie BG, Stock-Novack D, Salmon SE, et al:Prognostic value of pretreatment serum beta 2 microglobulin in myeloma:a Southwest Oncology Group Study. Blood　75：823-830，1990

7) Greipp PR, San Miguel J, Durie BG, et al:International staging system for multiple myeloma. J Clin Oncol　23：3412-3420，2005

8) Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders:a report of the International Myeloma Working Group. Br J Haematol　121：749-757，2003

9) Bataille R, Durie BG, Grenier J, et al:Prognostic factors and staging in multiple myeloma:a reappraisal. J Clin Oncol　4：80-87，1986

10) Bataille R, Boccadoro M, Klein B, et al:C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system. Blood　80：733-737，1992

11) Greipp PR, Lust JA, O'Fallon WM, et al:Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood　81：3382-3387，1993

12) San Miguel JF, Garca-Sanz R, Gonzalez M, et al:A new staging system for multiple myeloma based on the number of S-phase plasma cells. Blood　85：448-455，1995

13) Fonseca R, Bergsagel PL, Drach J, et al:International Myeloma Working Group molecular classification of multiple myeloma:spotlight review. Leukemia　23：2210-2221，2009

14) Lapierre LA, Fiers W, Pober JS:Three distinct classes of regulatory cytokines control endothelial cell MHC antigen expression. Interactions with immune gamma interferon differentiate the effects of tumor necrosis factor and lymphotoxin from those of leukocyte alpha and fibroblast beta interferons. J Exp Med　167：794-804，1988

15) Johnson DR, Pober JS:Tumor necrosis factor and immune interferon synergistically increase transcription of HLA class I heavy-and light-chain genes in vascular endothelium. Proc Natl Acad Sci USA　87：5183-5187，1990

16) Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma:an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group. J Clin Oncol　16：3832-3842，1998

17) Attal M, Harousseau JL, Stoppa AM, et al:A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Franais du Myelome. N Engl J Med　335：91-97，1996

18) Kumar SK, Rajkumar SV, Dispenzieri A, et al:Improved survival in multiple myeloma and the impact of novel therapies. Blood　111：2516-2520，2008

19) Richardson PG, Barlogie B, Berenson J, et al:Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma. Blood　106：2977-2981，2005

20) Ohguchi H, Sugawara T, Ishikawa I, et al:A retrospective analysis of bortezomib therapy for Japanese patients with relapsed or refractory multiple myeloma:beta2-microglobulin associated with time to progression. Int J Hematol　89：342-347，2009

21) Mateos MV, Hernandez JM, Hernandez MT, et al:Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma:updated time-to-events results and prognostic factors for time to progression. Haematologica　93：560-565，2008

22) Richardson PG, Sonneveld P, Schuster MW, et al:Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma. Br J Haematol　137：429-435，2007

23) San Miguel JF, Schlag R, Khuageva NK, et al:Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med　359：906-917，2008

24) Barlogie B, Desikan R, Eddlemon P, et al:Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide:identification of prognostic factors in a phase 2 study of 169 patients. Blood　98：492-494，2001

25) Mileshkin L, Biagi JJ, Mitchell P, et al:Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma:adverse prognostic impact of advanced age. Blood　102：69-77，2003

26) Palumbo A, Bringhen S, Falco P, et al:Time to first disease progression, but not beta2-microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy. Cancer　110：824-829，2007

27) Hattori Y, Okamoto S, Shimada N, et al:Single-institute phase 2 study of thalidomide treatment for refractory or relapsed multiple myeloma:prognostic factors and unique toxicity profile. Cancer Sci　99：1243-1250，2008

28) Barlogie B, Tricot G, Anaissie E, et al:Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med　354：1021-1030，2006

29) Lokhorst HM, van der Holt B, Zweegman S, et al:A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. Blood　115：1113-1120，2010

30) Palumbo A, Falco P, Corradini P, et al:Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma:a report from the GIMEMA--Italian Multiple Myeloma Network. J Clin Oncol　25：4459-4465，2007